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Introduction
Hepatic steatosis is characterized by the excessive accumulation 
of triglycerides as a consequence of an imbalance between the 
acquisition and disposal of fatty acids. Increased hepatic uptake of 
adipose tissue–derived fatty acids, defective breakdown via β-oxi-
dation, reduced VLDL-triglyceride secretion, and induced activity 
of master regulators of de novo lipogenesis, such as sterol element 
binding protein 1 (SREBP-1, encoded by Srebf1), are factors that 
contribute to the development of steatosis (1). Nonalcoholic fatty 
liver disease (NAFLD) comprises a spectrum of disorders, of which 
the earliest stage is characterized by the deposition of lipid drop-
lets within the cytoplasm of the hepatocytes. NAFLD increases the 
susceptibility to hepatocyte damage and inflammation, a condition 
termed nonalcoholic steatohepatitis (NASH), and can ultimately 
progress to cirrhosis and hepatocellular carcinoma (HCC) (1–4).
Liver receptor homolog 1 (LRH-1) is a nuclear receptor with 
diverse biological functions ranging from cell cycle regulation to 
the control of steroid homeostasis. In the liver, LRH-1 is an import-
ant regulator of glucose, cholesterol, and bile acid metabolism (5). 
Liver-specific Lrh-1 knockout mice display reduced glycolytic flux 
and de novo lipogenesis secondary to impaired glucokinase activity 
(6). On the other hand, treatment of mice with the LRH-1 agonist 
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) protects ani-
mals from developing NAFLD and insulin resistance in genetic and 
dietary models of diabesity (7, 8). To address this apparent contra-
dictory role of LRH-1 in hepatic triglyceride metabolism, we chose 
to study lipogenesis in our recently described Lrh-1 K289R knockin 
mouse model (LRH-1 K289R mice), which displays selective gain of 
function of LRH-1 as a result of impaired SUMOylation at K289 (9).
In this study, we demonstrate that LRH-1 K289R induces the 
expression of oxysterol binding protein-like 3 (OSBPL3, encoded by 
Osbpl3, also known as Orp3), which in turn promotes the posttrans-
lational activation of SREBP-1. As a consequence, LRH-1 K289R 
mice display increased de novo lipogenesis upon refeeding in com-
parison with WT mice. In fact, compared with what is seen in LRH-1 
WT mice, this chronic lipogenic stress promotes NAFLD in LRH-1 
K289R mice accompanied by early signs of NASH when mice are 
exposed to a lipogenic, high-fat, high-sucrose (HFHS) diet.
Results
Increased hepatic SREBP-1 processing in LRH-1 K289R mice. In order 
to evaluate the role of an LRH-1 SUMO–defective pathway on 
intermediary liver metabolism, we subjected LRH-1 K289R mice, 
which exhibit partial gain of function of LRH-1, and control LRH-1 
WT mice (9) to fasting-refeeding challenges in which mice were 
fasted and then refed for a period of 6 hours. We then evaluated 
the expression of metabolic genes in refed livers of both geno-
types using microarray analysis. Interestingly, the expression of 
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mental Figure 1, A and B; supplemental material available online 
with this article; https://doi.org/10.1172/JCI85499DS1) (10, 11), 
in LRH-1 K289R versus LRH-1 WT livers. Similarly, we did not 
observe differences in Srebf1a and Srebf1c expression in 2-, 6-, or 
12-hour–refed LRH-1 K289R and LRH-1 WT mice (Supplemental 
Figure 1C). Taken together, these data suggest that LRH-1 K289R 
induces SREBP-1 signaling primarily at the posttranscriptional 
level independently of early insulin-AKT signaling.
Enhanced de novo lipogenesis in LRH-1 K289R mice. To verify 
whether the increased expression of lipogenic genes is accompa-
nied by hepatic fat accumulation, we next quantified hepatic tri-
glyceride content in LRH-1 K289R and LRH-1 WT mice. The con-
tent of neutral lipids and triglycerides was significantly increased 
in LRH-1 K289R compared with LRH-1 WT livers upon refeeding 
(Figure 1, D and E). Of note, plasma triglycerides and free fatty 
many SREBP-1 target genes was increased in 6-hour–refed LRH-1 
K289R compared with LRH-1 WT livers, whereas SREBP-2 targets 
were not altered (Figure 1A). Although no changes in Srebf1 mRNA 
(Figure 1B) or uncleaved precursor SREBP-1 (Figure 1C) could 
be observed between both genotypes, refed LRH-1 K289R livers 
displayed significantly more of the cleaved and transcriptionally 
active SREBP-1 protein in comparison with the LRH-1 WT livers 
(Figure 1C), indicating that the posttranslational processing and 
maturation of SREBP-1 is increased in LRH-1 K289R mice. We 
then performed acute insulin challenges as well as shorter 2-hour 
refeeding experiments to analyze whether early signaling events 
could explain the increased SREBP-1 activity. Insulin did not 
induce an additional increase in AKT phosphorylation or a con-
sistent induction of early response genes, such as activating tran-
scription factor 3 (Atf3) or early growth response 1 (Egr1) (Supple-
Figure 1. LRH-1 K289R mice display increased de novo lipogenesis. (A) Heat map showing the expression of genes involved in de novo fatty acid and cho-
lesterol synthesis in refed WT and K289R mice. Normalized expression values are in log2 scale. SREBP-1, depicting mainly SREBP-1 target genes; SREBP-2, 
mostly SREBP-2 target genes; NS, transcripts that are not significantly changed between the indicated genotypes. For all other transcripts P < 0.05. (B) 
Hepatic mRNA expression of Srebf1 in K289R and WT mice. n = 10 per genotype. (C) Left, immunoblots of precursor and cleaved (cl) SREBP-1, SCD1, HSP90, 
and P62 in hepatic lysates of WT or K289R livers. Right, graph displaying the ratio of cleaved to precursor SREBP-1. (D) Representative images of liver 
sections of K289R or WT mice stained with oil red O to visualize neutral lipids. Scale bar: 200 μm. (E) Quantification of hepatic triglyceride content in WT 
and K289R mice. n = 10 per group. (F and G) Plasma triglyceride (TG) and free fatty acid (FFA) contents in WT and K289R mice. n = 10 per group. (H–J)  
Fractional de novo synthesis rates of palmitate (H), stearate (I), and oleate (J) in WT and K289R mice. n = 6 per group. Error bars represent mean ± SEM.  
*P < 0.05, **P < 0.01 relative to WT within each nutritional state; §P < 0.001 refed relative to fasted mice, as determined by unpaired Student’s t test (A) 
or 2-way ANOVA with Bonferroni’s post-hoc test (B, C, E–J). WT, LRH-1 WT; K289R, LRH-1 K289R mice.
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recently implicated in the shuttling of lipids between the plasma 
and endoplasmic reticulum membrane (12–14). The expression of 
Osbpl3, and to a lesser extent Osbpl1a, was robustly induced in LRH-1 
K289R livers, while that of most other OSBP family members did 
not differ between the 2 genotypes (Figure 2A). Of interest, overex-
pression of certain oxysterol-binding proteins has been suggested as 
increasing SREBP-1 processing and hepatic lipogenesis (15). Analy-
sis of livers of LRH-1 K289R versus LRH-1 WT mice confirmed the 
enhanced expression of Osbpl3 mRNA during fasting and refeeding 
(Figure 2B), while the expression of other OSBP family members 
did not differ between the 2 genotypes (Supplemental Figure 2A). 
Notably, the expression of Osbpl3 was high during fasting and then 
reduced upon refeeding (Figure 2B). This postprandial suppression 
of Osbpl3 mRNA expression was also observed upon overexpres-
sion of Osbpl3 in mice using an adenovirus (Supplemental Figure 
2B), suggesting that during the refed state, Osbpl3 is regulated by 
posttranscriptional mechanisms occurring independently of LRH-1. 
Despite this feeding-dependent regulation of the mRNA, hepatic 
Osbpl3 mRNA levels were consistently higher in the LRH-1 K289R 
acids did not show significant alterations between LRH-1 K289R 
and LRH-1 WT mice (Figure 1, F and G). To verify whether the 
enhanced expression of lipogenic genes translates into increased 
de novo lipogenesis, animals received 13C-acetate prior to sacri-
fice to quantify de novo lipogenesis (6). In line with the increased 
lipogenic gene expression, de novo synthesis of palmitate (C16:0), 
stearate (C18:0), and oleate (C18:1) was significantly higher in 
LRH-1 K289R compared with LRH-1 WT livers (Figure 1, H–J). Of 
note, chain elongation of preexisting fatty acids was not altered 
between the 2 genotypes (Supplemental Figure 1, D and E). Collec-
tively, these data show that LRH-1 K289R mice display increased 
de novo lipogenesis and that enhanced activation of SREBP-1 like-
ly contributes to this process.
SUMOylation-defective LRH-1 drives the expression of Osbpl3. We 
next analyzed the transcriptome of livers from refed LRH-1 K289R 
and LRH-1 WT mice and searched for transcripts that are linked to 
SREBP-1 processing. One of the top hits on the list of genes that was 
increased in LRH-1 K289R compared with LRH-1 WT livers cor-
responded to Osbpl3, a member of a class of lipid transfer proteins 
Figure 2. Osbpl3 is a direct LRH-1 target gene and overexpressed in LRH-1 K289R mice. (A) Heat map showing the hepatic expression of oxysterol-binding 
protein family members in WT and K289R mice. Normalized expression values are in log2 scale. (B and C) Expression of Osbpl3 mRNA in hepatic lysates 
of fasted and refed WT and K289R mice (B) and the fold change between the genotypes (C). n = 4 per fasted, 2-hour–, or 12-hour–refed groups, and n = 5 
per 6-hour–refed groups. (D) Expression levels of OSBPL3 protein in hepatic lysates of fasted and refed WT and K289R mice. (E) Schematic showing the 
genomic area containing the Osbpl3 gene and the sites used for ChIP-qPCR experiments (mouse genome assembly mm10). (F and G) Binding of LRH-1 to 
the different Osbpl3 promoter sites assessed by ChIP analysis using genomic DNA from fasted WT (F) and refed WT livers (G). n = 5 WT fasted, n = 5 WT 
refed. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, §P = 2 × 10–7 relative to WT, as determined by unpaired Student’s t test (A), or 
1-way (C) or 2-way (B, F, G) ANOVA with Bonferroni post-hoc test. TSS, transcription start site.
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LRH-1 target genes, including lipogenic genes, are coregulated by 
members of the LXR subfamily (20–22), we assessed the possibil-
ity that the LRH-1 mutant may modulate the recruitment of LXRα 
to its target genes, Abca1, Chrebp, and Srebf1. Although recruit-
ment of LXRα was detected on these promoters in the genom-
ic lysates of LRH-1 K289R and LRH-1 WT livers, no differences 
were observed between both genotypes, suggesting that LXRα 
binding is not altered due to the LRH-1 K289R mutation (Sup-
plemental Figure 3A). Furthermore, Hepa 1.6 and AML-12 cells 
treated with the LXR agonist GW3965 did not alter Osbpl3 expres-
sion (Supplemental Figure 3, B and C), indicating that Osbpl3 
expression is not regulated by LXR.
Osbpl3 silencing rescues the steatotic phenotype of LRH-1 K289R 
mice. To establish whether the increased expression of OSBPL3 in 
LRH-1 K289R livers is causatively linked to exacerbated de novo 
lipogenesis, we performed in vivo overexpression and silencing 
experiments. Adenoviral overexpression of OSBPL3 increased 
mice in all nutritional states, but were particularly high under 
6-hour–refeeding conditions (Figure 2C), and these differences 
were translated into similar changes at the protein level (Figure 2D).
To investigate whether Osbpl3 is directly controlled by LRH-1, 
we first analyzed the Osbpl3 genomic region in available ChIP-Seq 
data for potential LRH-1–binding sites (16, 17). We identified 3 
main sites from the ChIP-Seq data from Holmstrom et al. (sites 1–3; 
ref. 16), and 3 additional sites with an LRH-1 consensus sequence 
close to one of the transcription start sites of the Osbpl3 gene (sites 
4–6) were identified by computational analysis (Figure 2E). We 
then performed site-specific ChIP analysis to evaluate whether 
these sites are bound by LRH-1 in fasted and refed mice. LRH-1 was 
recruited at different sites under both nutritional conditions (Fig-
ure 2, F and G), suggesting that Osbpl3 is a direct LRH-1 target gene.
Based on the fact that LRH-1 and the nuclear receptor liver X 
receptor (LXR) have been shown to crosstalk in the regulation of 
hepatic acute-phase response proteins (18, 19) and that various 
Figure 3. Osbpl3 silencing rescues the lipogenic phenotype of LRH-1 K289R mice. (A) Immunoblots of OSBPL3, HSP90, precursor and cleaved SREBP-1, 
P62, and HDAC3 in hepatic lysates of fasted or refed WT plus Ad-GFP or refed WT plus Ad-OSBPL3 livers. (B–D) Hepatic mRNA expression of Osbpl3 (B), 
Srebf1 (C), and Fasn (D) in refed K289R and WT mice. WT, n = 3; K289R siScr or K289R siOsbpl3, n = 9 per genotype. (E) Immunoblots of OSBPL3, FASN, 
β-actin, precursor and cleaved SREBP-1, and PARP1 in hepatic lysates of refed K289R siScr or K289R siOsbpl3 livers. (F) Hepatic expression of OSBPL3, 
FASN, SCD1, and HSP90 in livers of ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. (G) Hepatic mRNA expression of genes involved in de novo 
lipogenesis in ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. n = 3 per genotype. (H) Quantification of hepatic triglycerides in hepatic lipid 
extracts from ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. n = 3 per genotype. (I and J) Hepatic mRNA expression of Osbpl3 (I) and Fasn 
(J) in 6-hour–refed WT, K289R, or K289R mirOsbpl3 mice. n = 3 per genotype. (K) Representative oil red O staining in liver cryosections from refed K289R 
mirScrambled or K289R mirOsbpl3 mice. Scale bars: 100 μm. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 relative to K289R siScr, 
as determined by 1-way ANOVA with Bonferroni’s post-hoc test (B–D, G–J). WT, LRH-1 WT; K289R siOsbpl3, LRH-1 K289R mice injected with Osbpl3- 
siRNA complexes; K289R siScr, LRH-1 K289R mice injected with scrambled-siRNA complexes; K289R mirOsbpl3, LRH-1 K289R mice injected with AAV8 
viral vectors containing an miRNA targeting Osbpl3.
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expression levels of the lipogenic enzymes acetyl–coenzyme A 
carboxylase alpha (Acaca), Fasn, Scd1, and glycerol-3-phosphate 
acyltransferase (Gpam) were often normalized to values observed 
in LRH-1 WT mice (Figure 3G), suggesting that Osbpl3 silencing 
rescues the lipogenic phenotype of LRH-1 K289R mice. In line 
with the reduced expression of lipogenic genes, Osbpl3 silencing 
also decreased hepatic triglyceride and neutral lipid content (Fig-
ure 3H). As an additional approach to silence Osbpl3, we injected 
mice with an AAV8 viral vector containing an miRNA targeting 
Osbpl3 in the liver. Here again, we observed a robust silencing of 
Osbpl3, which was accompanied by the suppression of Fasn and a 
striking reduction of hepatic lipid droplets (Figure 3, I–K).
Finally, we also examined whether other mechanisms, direct-
ly or indirectly regulated by LRH-1, may contribute to the lipo-
genic phenotype. Of interest, both hepatic glucose-6-phosphate 
content (6) and VLDL secretion (23) were unchanged between 
SREBP-1 cleavage in refed LRH-1 WT mice (Figure 3A), suggest-
ing that elevated OSBPL3 levels promote SREBP-1 activation. We 
next silenced Osbpl3 in LRH-1 K289R mice using siRNAs in LRH-1 
K289R mice under fast-refeeding conditions. The hepatic mRNA 
expression of Osbpl3 showed a clear trend of effective silencing 
(Figure 3B), while Srebf1 expression was not altered (Figure 3C). 
Importantly, we observed a robust decrease in OSBPL3 protein 
along with a reduction in the maturation of SREBP-1 and a blunted 
expression of the fatty acid synthase (FASN) transcript and pro-
tein in the livers of refed LRH-1 K289R mice treated with siOsbpl3 
(Figure 3, D and E). We next assessed the effect of Osbpl3 silenc-
ing under normal-fed conditions. Western blot analysis revealed 
reduced OSBPL3 expression (Figure 3F) and a robust decrease in 
the lipogenic proteins FASN and stearoyl–coenzyme A desaturase 1 
(SCD-1) in ad libitum–fed LRH-1 K289R mice treated with siOsbpl3 
compared with control mice (Figure 3F). Of interest, mRNA 
Figure 4. LRH-1 K289R mice develop NAFLD upon HFHS diet feeding. (A) Representative images of liver sections of K289R or WT mice stained with 
H&E or oil red O to visualize the tissue structure and neutral lipids, respectively. Black scale bar: 200 μm; white scale bar: 50 μm. (B and C) Quantification 
of triglyceride content in plasma (B) and in hepatic lipid extracts (C) in WT and K289R mice. WT, n = 7; K289R, n = 10. (D and E) Plasma levels of ALAT (D) 
and ASAT (E) in mice fed a HFHS diet. WT, n = 7; K289R, n = 10. (F and G) Expression of Osbpl3 mRNA (F) and protein (G) levels in livers of WT and K289R 
mice fed chow and HFHS diets. n = 9 per genotype. (H) Heat map displaying the expression of Osbpl3 as well as markers of matrix degradation, fibrosis, 
and inflammation in mice that were classified as LFL responders, LFH responders, HFL responders, and HFH responders according to the development 
of NAFLD/NASH upon chow or high-fat diet feedin g (24). (I) Expression of OSBPL3 and markers of matrix degradation, fibrosis, and inflammation in 
transcriptomic data from human patients that were categorized for mild or advanced NAFLD (25). Normalized expression values are in log2 scale. Error bars 
represent mean ± SEM. **P < 0.01, ***P < 0.001 relative to WT; §P < 0.001 refed relative to fasted mice, as determined by unpaired Student’s t test (B, D, 
E) or 2-way ANOVA with Bonferroni’s post-hoc test (C, F).
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LRH-1 K289R and LRH-1 WT mice (Supplemental Figure 4, A–C), 
making it unlikely that these processes account for the exacerbat-
ed lipid accumulation in liver.
Together, these data suggest that the LRH-1-OSBPL3 signal-
ing axis contributes to the increased maturation of SREBP-1, the 
induction of lipogenic enzymes, and the hepatic accumulation of 
triglycerides observed in LRH-1 K289R mice.
LRH-1 K289R mice are prone to developing NAFLD upon lipo-
genic diet feeding. Excessive de novo lipogenesis contributes to the 
development of NAFLD, a condition that can eventually progress 
to NASH (1, 3). In order to investigate whether LRH-1 affects the 
development of NAFLD, LRH-1 K289R and LRH-1 WT mice were 
fed a highly lipogenic HFHS diet or a chow diet for 17 weeks, and 
then sacrificed under normal-fed conditions. Stainings of hepatic 
sections with H&E and oil red O revealed that LRH-1 K289R mice 
developed a stronger steatotic phenotype compared with LRH-1 
WT mice fed a HFHS diet (Figure 4A). While plasma cholester-
ol levels were unchanged (Supplemental Figure 5A), triglyceride 
content in plasma (Figure 4B) or in VLDL fractions (Supplemen-
tal Figure 5B) was reduced in HFHS-fed LRH-1 K289R mice. This 
reduction was accompanied with a robust accumulation of hepatic 
triglycerides (Figure 4C) as well as an induction of plasma levels of 
the enzymes alanine transaminase (ALAT) and aspartate amino-
transferase (ASAT) in the HFHS-challenged LRH-1 K289R mice 
(Figure 4, D and E). Similar to our earlier observations in normal 
chow diet conditions (Figure 2, A–D), Osbpl3 mRNA and OSBPL3 
protein were significantly induced in LRH-1 K289R compared 
with LRH-1 WT mice fed a HFHS diet (Figure 4, F and G), while 
the expression of other Osbp genes did not differ between the gen-
otypes (Supplemental Figure 5C).
The development of hepatic steatosis in mice is known to be 
highly heterogeneous (24). Therefore, we analyzed the data from a 
study in which mice were fed a chow or high-fat diet and then clas-
sified according to the development of NAFLD/NASH into low-
fat low (LFL) responders, low-fat high (LFH) responders, high-fat 
low (HFL) responders, and high-fat high (HFH) responders (24). 
Interestingly, the expression of Osbpl3 was significantly induced 
in the HFH responders along with markers of inflammation and 
Figure 5. LRH-1 K289R mice display increased inflammation and early signs of fibrosis upon HFHS diet feeding. (A) Representative images of liver 
sections of K289R or WT mice stained with sirius red or CD45 to visualize collagen depositions and CD45-positive cells, respectively. Scale bars: 200 μm. CV, 
central vein. (B–E) Hepatic mRNA expression of genes involved in inflammation (B), matrix degradation (C), fibrosis (D), and stellate cells (E) in K289R and 
WT mice. n = 9 per genotype. (F) Graphical presentation showing how the LRH-1/OSBPL3 axis drives the accumulation of hepatic lipids. Error bars represent 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 relative to WT within each diet, as determined by 2-way ANOVA with Bonferroni’s post-hoc test (B–E).
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necrosis (Figure 4H) and was by far the most strikingly increased 
Osbp among all family members (Supplemental Figure 5D). We 
also analyzed OSBPL3 expression in 2 cohorts of NAFLD/NASH 
patients. In the first cohort, livers were categorized as showing 
mild or advanced NAFLD (25). In the second study, subjects had 
livers ranging from healthy controls to showing steatosis and fur-
ther to NASH (26). OSBPL3 expression was low in healthy livers, 
but increased in advanced stages of NAFLD/NASH and clustered 
with markers of fibrosis (Figure 4I and Supplemental Figure 6), 
suggesting that OSBPL3 could be a novel biomarker for advanced 
liver diseases, such as NASH. Taken together, these data show that 
Osbpl3 is markedly increased in LRH-1 K289R mice as well as in 
mice and humans with NAFLD/NASH.
LRH-1 K289R mice display increased inflammation and early 
signs of fibrosis in response to lipogenic diet feeding. Given the strong 
steatotic phenotype and the high levels of ALAT and ASAT mark-
ers in LRH-1 K289R mice fed a HFHS diet as well as the cluster-
ing of Osbpl3 with genes involved in inflammation and fibrosis 
in mice and humans with NAFLD, we next analyzed inflamma-
tory and fibrotic markers in LRH-1 K289R and LRH-1 WT mice. 
Stainings of hepatic sections with sirius red and CD45 revealed 
that, in contrast with LRH-1 WT mice, LRH-1 K289R mice devel-
oped small fibrotic lesions and accumulated CD45-positive 
immune cells upon HFHS feeding (Figure 5A). Moreover, LRH-1 
K289R livers displayed higher levels of the inflammatory genes 
Tnfα, monocyte chemoattractant protein-1 (Mcp1 or Ccl2), and 
macrophage inflammatory protein-1 α (Mip1α or Ccl3) (Figure 
5B), indicating increased inflammation in livers of HFHS-fed 
LRH-1 K289R mice. The expression of MMPs, such as Mmp2 
and Mmp13, as well as early markers of fibrosis, such as α-1 type I 
collagen (Col1a1) and Tgfb1, was also elevated in LRH-1 K289R 
in comparison with LRH-1 WT mice fed a HFHS diet (Figure 5, 
C and D). Hepatic stellate cells are the primary hepatic cell type 
promoting fibrogenesis (27). The expression of different hepatic 
stellate cell markers, such as desmin (Des), glial fibrillary acidic 
protein (Gfap), and reelin (Reln), was also increased in HFHS-
fed LRH-1 K289R compared with LRH-1 WT mice (Figure 5E), 
suggesting that HFHS-treated LRH-1 K289R mice exhibit early 
signs of NASH.
Previous studies showed that LRH-1 and the SUMOylation 
machinery might affect the hepatic acute phase response (APR) 
(18, 19, 28). While induction of the APR by short exposure of LPS 
led to reduced hepatic expression of Crp and Tnf in LRH-1 K289R 
compared with LRH-1 WT mice, it did not alter the hepatic expres-
sion of other APR and inflammatory genes (Supplemental Figure 
7A). Moreover, no difference in plasma IL-6, MCP-1 (also known 
as CCL-2), or TNF-α could be observed in LPS-challenged LRH-1 
K289R and LRH-1 WT mice (Supplemental Figure 7B), suggesting 
that the APR is likely not driving the observed inflammatory phe-
notype in our NAFLD-model.
Taken together, these data show that SUMOylation-defective 
LRH-1 promotes the development of NAFLD and displays early 
signs of NASH in mice fed a HFHS diet. This process is at least 
partially driven by the LRH-1-OSBPL3 signaling axis, which con-
tributes to increased maturation of SREBP-1, the induction of lipo-
genic enzyme expression, and hepatic triglyceride accumulation 
in LRH-1 K289R mice (Figure 5F).
Discussion
In this study, we analyzed the contribution of a selective LRH-1 
gain of function on hepatic de novo lipogenesis and fatty liver 
development and identified Osbpl3 as a critical component in the 
regulation of this process. While the hepatic expression of Osbpl3 is 
normally low in mice under basal conditions, LRH-1 K289R mice 
express high levels of this specific OSBP family member. Consis-
tent with our observations, the analyses of independent mouse 
and human transcriptomic data sets revealed that Osbpl3 expres-
sion is often induced in NAFLD/NASH. Our work furthermore 
strengthens the putative role of OSBPL3 in SREBP-1 maturation. 
As a consequence, LRH-1 K289R mice display increased de novo 
lipogenesis and accumulation of triglycerides upon refeeding 
in a manner that is independent of enhanced LXRα recruitment 
or activity. Importantly, silencing of OSBPL3 in vivo reverts the 
increased lipogenesis observed in these animals. Moreover, when 
exposed to a lipogenic HFHS diet, LRH-1 K289R mice develop 
NAFLD accompanied by early signs of NASH, most likely as a con-
sequence of chronic fat accumulation (1, 3).
The excessive accumulation of hepatic lipids and increased de 
novo lipogenesis could also have other causes. A previous study 
using liver-specific Lrh-1 knockout mice showed that LRH-1 pro-
motes glucokinase expression, hence regulating glycolysis and de 
novo lipogenesis (6). However, we did not observe a difference 
in hepatic glucose-6-phosphate content between LRH-1 WT and 
LRH-1 K289R mice, suggesting that the selective gain of function 
of LRH-1 driven by the K289R mutation does not increase substrate 
availability for the glycolytic pathway. Based on the finding that 
the primary corepressor of LRH-1 affects microsomal triglyceride 
transfer protein levels and consequently hepatic VLDL-triglyceride 
secretion (23), we also performed in vivo VLDL-secretion assays, 
but could not detect any difference between refed LRH-1 K289R 
and LRH-1 WT mice. Finally, LRH-1 SUMOylation has been linked 
to the induction of the hepatic APR (18, 19, 28), which could explain 
the excessive inflammation observed in the livers of mice receiv-
ing a chronic HFHS diet. To study the APR in vivo, we challenged 
LRH-1 WT and LRH-1 K289R mice with lipopolysaccharide for 2.5 
hours. Besides the reduction in Crp and Tnf, the inflammatory sig-
nature was comparable between the genotypes, suggesting that the 
exacerbated inflammatory phenotype of the LRH-1 K289R mice is 
most likely not driven by changes in the APR.
While the induction of SREBP-2 processing has been well 
described, the mechanisms that trigger SREBP-1 processing are 
less well understood (29). Insulin receptor/AKT/mTOR signaling 
is considered one of the main pathways triggering SREBP-1 sig-
naling (30). A recent study showed that insulin promotes SREBP-1 
activation and de novo lipogenesis via mTORC1-dependent 
and -independent mechanisms (31). Others proposed that while 
insulin signaling is required for SREBP-1 activation in insulin- 
resistant conditions, it is not critical for inducing the feeding- 
dependent induction of SREBP-1 under physiological conditions 
(32, 33). In breast epithelial cells, the expression of oncogenic 
forms of the PI3K or K-Ras are sufficient to induce SREBP-1 matu-
ration and de novo lipogenesis through induction of mTOR signal-
ing (34). Whereas these and many other studies demonstrate that 
the expression of Srebf1 and the posttranslational maturation of 
SREBP-1 can be triggered by insulin signaling, other downstream 
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old male mice were initially fasted for 24 hours, followed by refeeding 
for 12 hours (8 pm to 8 am), 6 hours (2 am to 8 am), or 2 hours (6 am 
to 8 am), and finally sacrificed together at 8 am to avoid confounding 
effects of the circadian rhythm. To induce a chronic hepatic steatosis, 
male mice were fed ad libitum with a HFHS diet (TD.08811, Harlan 
Laboratories) for 17 weeks and sacrificed at 9 am. To study the APR, 
male mice fed a chow diet received an intraperitoneal injection of 
either 500 μl PBS or 40 μg LPS dissolved in 500 μl PBS. Mice were 
sacrificed 2.5 hours after injection and tissues collected.
Subcellular fractionation of liver tissues and Western blotting. From 
50 to 100 mg of liver pieces were incubated in 400 μl of hypotonic buf-
fer (10 mM HEPES-KOH, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM 
DTT, protease and phosphatase inhibitor cocktails; Roche) and lysed 
with 10 strokes in a Dounce homogenizer. The supernatant fraction 
containing mainly cytoplasmic proteins was collected after centrifuga-
tion (14,000 g for 5 minutes, 4°C), and the pellets were washed twice 
with hypotonic buffer. The pellets were resuspended in 100 to 200 μl 
of hypertonic buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1 % 
NP-40, protease and phosphatase inhibitor cocktails) for 30 minutes 
on ice. The supernatant containing mainly nucleoplasm and mem-
brane fractions was collected by centrifugation (2,000 g for 5 minutes, 
4°C), and the remaining insoluble pellet containing mainly chromatin 
was resuspended in 100 μl of hypertonic buffer and sonicated. Before 
running SDS-PAGE, protein lysates were boiled for 5 minutes at 95°C. 
The following proteins were used for Western blotting: anti-Hsp90, 
anti–SREBP-1, and anti-P62 (BD Biosciences catalog 610418, 557036, 
and 610497); anti-OSBPL3 (Novus Biologicals, catalog NBP-155151), 
anti-FASN (Abcam, catalog ab22759), anti-SCD1 (Thermo Fisher, 
catalog A13996), anti–α-tubulin, anti-PARP1, and anti–β-actin (San-
ta Cruz Biotechnology Inc., catalog sc-5286, sc-7150, and sc-47778). 
Anti–SREBP-1, anti-P62, and anti-PARP1 were blotted on nuclear/
membrane fractions and all other antibodies on cytoplasmic fractions.
Gene expression and analysis. RNA was extracted from the livers of 
mice that were fasted for 24 hours followed by 6 hours of refeeding, 
LRH-1 WT (n = 6) and LRH-1 K289R (n = 6). Extraction was performed 
using TRIZOL (Invitrogen) and purified with the RNeasy Cleanup Kit 
for Microarray Analysis (QIAGEN). For quantitative reverse-tran-
scription PCR (RT-qPCR), cDNA was generated using the QuantiTect 
Reverse Transcription Kit (QIAGEN) and analyzed by qPCR using a 
LightCycler 480 Real-Time PCR System (Roche) and the primers list-
ed in Supplemental Table 1. Expression data were normalized to 36b4 
or B2m mRNA levels. Microarray analysis was performed using the 
Affymetrix MouseGene 1.0 ST array and normalized using the robust 
multi-array average (RMA) method. All original microarray data were 
deposited in the NCBI’s Gene Expression Omnibus (GEO GSE89877). 
Heat maps were generated using GENE-E (http://www.broadinstitute. 
org/cancer/software/GENE-E/index.html), and rows were clustered 
using the one minus Pearson correlation metric.
ChIP-PCR. ChIP analysis was performed as described previous-
ly, with minor modifications (9). ChIPed DNA was purified using the 
PCR Clean-up Extraction Kit (Macherey-Nagel), after which qPCR 
was performed as described previously (47). Data were normalized to 
the input (fold differences = 2– (Ct-sample – Ct-input)). ChIP primer sequences 
are listed in Supplemental Table 2. For LXR ChIP assays, an anti-LXRα 
antibody (Abcam, catalog ab41902) was used. For LRH-1 ChIP exper-
iments, a custom LRH-1 antibody was generated. A synthetic peptide 
([H]-QEQSNRNRQEKLSAFG-[NH2]) was used to immunize 2 rab-
or parallel pathways exist. One recent example is the induction of 
SREBP-1 processing upon depletion of phosphatidylcholine, whose 
synthesis is dependent on S-adenosylmethionine, a methionine 
derivative that is generated in the one-carbon cycle (35). We did 
not observe a difference in AKT phosphorylation between LRH-1 
WT and LRH-1 K289R mice, suggesting other signaling pathways 
to induce the processing of SREBP-1. Indeed, our current study 
highlights the existence of an alternative mechanism of SREBP-1 
activation involving a SUMO-dependent LRH-1/OSBPL3 pathway.
The first oxysterol-binding proteins were identified, puri-
fied, and cloned in the 1980s (36–38). Recent studies suggest that 
OSBPs act as sterol transfer and/or sensor proteins that may also 
play important roles in cell signaling (39, 40). OSBPL3, a mem-
ber of subfamily III, contains a conserved sterol-binding OSBP 
homology domain (OHD) as well as a phosphatidylinositol lipid 
species–binding pleckstrin homology (PH) domain and two 2-phe-
nylalanines in an acidic tract (FFAT) domains that bind to the ves-
icle-associated membrane protein–associated (VAMP-associated) 
protein (VAP) (39, 41, 42). Recently, it has been shown that this 
last interaction can activate R-RAS, thus reorganizing the actin 
cytoskeleton and affecting cell polarity and cell-cell adhesion (43). 
Future studies will be necessary to dissect the exact mechanisms 
by which OSBPL3 modulates SREBP-1 processing, but its associa-
tion with the ER could indicate a possible site of regulation.
In addition to the identification of OSBPL3 as a target of LRH-1, 
our study also highlights the existence of complex regulatory 
mechanisms to which OSBPL3 is subjected. We observed a discrep-
ancy between mRNA and protein levels of OSBPL3 between fast-
ing and refed conditions despite its persistent increase in LRH-1 
K289R mice. The marked reduction in mRNA levels upon refeed-
ing was also noticed when OSBPL3 was overexpressed using an 
adenovirus, indicating that additional posttranscriptional mecha-
nisms independent of LRH-1 regulate the expression of OSBPL3. 
Moreover, while the expression of OSBPL3 is low in healthy livers, 
it is increased in NAFLD, suggesting that this protein could be a 
novel biomarker for NAFLD.
In this study, we described a function of LRH-1 in the devel-
opment of fatty liver disease. It is noteworthy that other nuclear 
receptors also contribute to the development of NAFLD by affect-
ing steatosis, glucose homeostasis, inflammation, and/or fibrosis 
in the liver. For instance, while activation of LXRs or pregnane 
x receptor (PXR) promotes lipogenesis and the development of 
NAFLD, activation of other nuclear receptors such as PPARs 
or farnesoid X-activated receptor (FXR) has opposite effects 
(reviewed in ref. 44). Clinical trials performed in NASH patients 
using PPARγ or FXR agonists showed that the beneficial effects 
observed on hepatic steatosis and inflammation were accom-
panied by adverse effects on obesity and hypercholesterolemia, 
respectively (45, 46), highlighting the functional complexity of 
nuclear receptors (44). Therefore, the development of drugs tar-
geting specific nuclear receptor targets, such as OSBPL3, might 
provide alternative therapeutic options for treating NAFLD.
Methods
Animal studies. Congenic C57BL/6J LRH-1 WT or LRH-1 K289R (9) as 
well as C57BL/6J Lrh-1hep–/– and Lrh-1hep+/+ mice (6) were kept under nor-
mal housing conditions. For fast-refeeding protocols, 12- to 16-week-
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Immunohistochemistry. Liver sections were cut into 5-μm–thick seri-
al cryosections for oil red O staining to visualize neutral lipids or paraffin 
cryosections to stain collagen with sirius red, CD45-positive cells using 
rat anti-CD45 antibody (eBioscience, catalog 30-F11), or H&E.
Statistics. Data are expressed as mean ± SEM. Comparison of differ-
ences between 2 groups was assessed using unpaired 2-tailed Student’s 
t tests. Multiple group comparisons were assessed by ANOVA and Bon-
ferroni’s post-hoc t tests. P < 0.05 was considered statistically significant.
Study approval. All animal procedures were approved by the 
Swiss authorities (Canton of Vaud, animal protocols ID 2380, 2561, 
and 2768) and performed in accordance with École Polytechnique 
Fédérale de Lausanne institutional guidelines.
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bits (AbFRONTIER). The antiserum with the highest ELISA titer was 
selected and used in ChIP experiments. The preimmunization serum 
from the same rabbit was used as a negative control.
LXR agonist treatment. Hepa 1.6 (ATCC, catalog CRL1830) or 
AML-12 (ATCC, catalog CRL2254) cells were treated with 1 μM of 
GW3965 (Selleckchem), a dual LXRα and LXRβ agonist, for 6 hours 
in full medium.
In vivo siRNA transfection. siRNA sequences are listed in Supple-
mental Table 4. HPLC-purified siRNAs (3 nmol, Microsynth) were tail-
vein injected into each recipient mouse using in vivo-JetPEI (Polyplus) 
according to the manufacturer’s instructions. Mice were fast-refed as 
described above and sacrificed 2 days after injection.
Adenoviral infection. Osbpl3 cDNA was cloned into a pENTR/ 
D-TOPO plasmid (Invitrogen; the Topo primer is listed in Supple-
mental Table 3) and then subcloned in the pAd/CMV-DEST plasmid 
(Invitrogen). After linearization with PacI, the construct was trans-
fected into HEK 293A cells to produce the adenoviruses. Mice were 
tail-vein injected with Ad-gfp or Ad-Osbpl3, 2.5 × 109 PFU, fast-refed as 
described above, and sacrificed 3 days after injection.
AAV8 miRNA injection. The Osbpl3-siRNA sequence (Supplemen-
tal Table 4) was engineered to create a pre-miRNA sequence target-
ing Osbpl3, which was cloned into an AAV vector construct driven by 
the liver-specific hAAT promoter. AAV8 mirOsbpl3 viral vectors were 
generated and titrated as described previously (48, 49) and injected 
into jugular vein under isoflurane anesthesia (5 × 1011 vg). Two weeks 
after the injection, mice were fasted for 24 hours followed by 6 hours 
refeeding, then sacrificed, and tissues were snap-frozen.
Lipid analyses and plasma parameters. Hepatic lipids were extract-
ed according to the Bligh and Dyer protocol (50). Triglycerides, free 
fatty acids, and cholesterol contents in plasma and/or hepatic lipid 
fractions were quantified using enzymatic assays (Roche). To asses 
fatty acid synthesis rates in vivo, mice received sodium [1-13C] ace-
tate via their drinking water (2%) 24 hours prior to sacrifice. Fatty 
acids derived from hepatic lipid extracts were liberated, derivatized, 
and subjected to gas chromatography–mass spectrometry (GC-MS) 
analysis in order to calculate the fractional synthesis rates from the 
incorporation of 13C-acetate as described previously (51). ASAT and 
ALAT concentrations in blood were determined using standard clin-
ical chemistry methods.
VLDL secretion assay and glucose-6-phosphate quantification. The 
VLDL secretion assay was performed as described previously (51). 
Thirteen-week-old male LRH-1 K289R or LRH-1 WT mice were sub-
jected to the fasting-refeeding protocol and treated with 50 mg/ml 
poloxamer 407 (Sigma-Aldrich, catalog 16758) 8 hours after refeed-
ing was initiated. Blood samples were collected once before and every 
hour after poloxamer treatment to determine the triglyceride content. 
Glucose-6-phosphate content was determined using enzymatic assays 
as described previously (6).
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